Common Contracts
4 similar Settlement and License Agreement contracts by Biogen Inc.
Biogen Swiss Manufacturing GmbH Biogen International Holding Ltd. c/o Biogen Inc.Settlement and License Agreement • November 30th, 2020 • New York
We refer to the proposed Settlement and License Agreement attached hereto as Exhibit A to be entered into by Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd, Forward Pharma A/S and each of the parties listed on Appendix I thereto, to be dated as of the date of this letter agreement (the “License Agreement”). Capitalized terms used and not defined in this letter agreement (the “Agreement”) shall have the meaning ascribed in the License Agreement.
SETTLEMENT AND LICENSE AGREEMENT among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma A/S and Each of the Parties Listed on Appendix I Dated as of January 17, 2017Settlement and License Agreement • November 20th, 2020 • New York
Pursuant to 35 U.S.C. § 135(c), 37 C.F.R. § 41.205, and ¶ 205 of the Standing Order (Paper 2), Junior Party Biogen MA Inc. and Senior Party Forward Pharma A/S hereby give notice that the parties have made a written agreement relating to the Interference.
SETTLEMENT AND LICENSE AGREEMENT among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma A/S and Each of the Parties Listed on Appendix I Dated as of January 17, 2017Settlement and License Agreement • February 1st, 2017 • Biogen Inc. • Biological products, (no disgnostic substances) • New York
SETTLEMENT AND LICENSE AGREEMENT (this “Agreement”) dated as of the Agreement Date (as defined below), among each of the following Parties:
Biogen Swiss Manufacturing GmbH Biogen International Holding Ltd. c/o Biogen Inc. Cambridge, MA 20142Settlement and License Agreement • January 17th, 2017 • Biogen Inc. • Biological products, (no disgnostic substances) • New York
We refer to the proposed Settlement and License Agreement attached hereto as Exhibit A to be entered into by Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd, Forward Pharma A/S and each of the parties listed on Appendix I thereto, to be dated as of the date of this letter agreement (the “License Agreement”). Capitalized terms used and not defined in this letter agreement (the “Agreement”) shall have the meaning ascribed in the License Agreement.
